Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy.

International journal of oncology - 1 Oct 2012

Okita Yoshiko, Narita Yoshitaka, Miyakita Yasuji, Ohno Makoto, Matsushita Yuko, Fukushima Shintaro, Sumi Minako, Ichimura Koichi, Kayama Takamasa, Shibui Soichiro

Abstract excerpt

Reliable prognostic biomarkers of grade II gliomas remain unclear. This study aimed to examine the role of mutations of isocitrate dehydrogenase (IDH1/2), 1p/19q co-deletion, and clinicopathological factors in patients with grade II glioma who were primarily treated with radiotherapy or chemoradiotherapy after surgery. Seventy-two consecutive patients, including 49 cases of diffuse astrocytomas (DA), 4...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Astrocytoma
Share to Biomarkers, Pharmacological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Disease-Free Survival

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Oligodendroglioma

Share to Prognosis

Source

Identifiers

PMID: 22825915
DOI: 10.3892/ijo.2012.1564

Genes

IDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy.PMID 22825915Read ↗

Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas.Semantic proximity Read ↗

A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy.Semantic proximity Read ↗

IDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma.Semantic proximity Read ↗

IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis.Semantic proximity Read ↗

Oligodendroglioma, IDH-mutant and 1p/19q-codeleted-prognostic factors, standard of care and chemotherapy, and future perspectives with neoadjuvant strategy.Semantic proximity Read ↗

Isocitrate Dehydrogenase IDH1 and IDH2 Mutations in Human Cancer: Prognostic Implications for Gliomas.Semantic proximity Read ↗

Glioblastomas with IDH1/2 mutations have a short clinical history and have a favorable clinical outcome.Semantic proximity Read ↗

Molecular classification of low-grade diffuse gliomas.Semantic proximity Read ↗

1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas.Semantic proximity Read ↗

New insights into glioma classification based on isocitrate dehydrogenase 1 and 2 gene status.Semantic proximity Read ↗

Unlocking new horizons: advances in treating IDH-mutant, 1p/19q-codeleted oligodendrogliomasSemantic proximity Read ↗

Clinico-neuropathological features of isocitrate dehydrogenase 2 gene mutations in lower-grade gliomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.